-Oral presentation on June 1, 2024-
TARRYTOWN, N.Y., May 23, 2024
/PRNewswire/ -- Sapience Therapeutics, Inc., a clinical-stage
biotechnology company focused on the discovery and development of
peptide therapeutics to address oncogenic and immune dysregulation
that drive cancer, today announced that clinical and biomarker data
from its ST101 Phase 2 study in GBM will be delivered during an
oral presentation on June 1, 2024 at
the upcoming 2024 American Society of Clinical Oncology (ASCO)
Annual Meeting.
ST101 is a first-in-class antagonist of C/EBPβ, currently being
evaluated in patients with recurrent and newly diagnosed GBM in the
Phase 2 portion of an ongoing Phase 1-2 clinical study
(NCT04478279).
Sapience's Chief Medical Officer, Abi
Vainstein-Haras, MD, stated, "We are encouraged by ST101's
clinical and biomarker data for patients with glioblastoma.
This novel therapy has the potential to be a new treatment
opportunity for this devastating disease, and we are honored to be
presenting these promising results in an oral presentation at ASCO
2024. We are committed to bringing new hope to patients battling
glioblastoma and look forward to advancing ST101 through clinical
development."
Dr. Fabio M. Iwamoto, Division of
Neuro-Oncology, New York-Presbyterian/Columbia
University Irving Medical Center, and Principal
Investigator of the ST101-101 clinical study added, "Current
treatments for recurrent glioblastoma offer limited hope for
patients. I'm enthusiastic about the potential of ST101. It
represents a novel approach with the potential to extend survival,
both as a standalone therapy and in combination with existing
treatments. Importantly, ST101's safety profile suggests it could
be well-tolerated, potentially offering a significant benefit for
patients battling this aggressive disease."
Oral presentation details and abstract highlights
include:
Abstract Title: "Efficacy and biomarker analysis
of phase 2 (P2) and window-of-opportunity (WoO) cohorts of patients
with glioblastoma (GBM) treated with ST101, an inhibitor of the
transcription factor C/EBPβ"
Abstract Number for Publication: 2011
Session Type and Title: Clinical Science Symposium –
Advancing Trial Design: Illuminating Tumor Evolution in Central
Nervous System Cancer
Date and Time: 6/1/2024, 3:00
PM-4:30 PM CDT
Presenting Author: Fabio M. Iwamoto, MD, Division of
Neuro-Oncology, New York-Presbyterian/Columbia
University Irving Medical Center
- ST101 has the potential to be a well-tolerated treatment option
for patients with GBM
- Outcome data to be presented from multiple cohorts of GBM
patients
- Main study: monotherapy in recurrent GBM
- Window-of-Opportunity Study: mono/combination-therapy in
GBM
- Biomarker data to be presented from Window-of-Opportunity study
cohorts
- ST101 crosses the BBB and penetrates tumor tissue as shown by
IHC
- Target (C/EBPβ) engagement and degradation shown by IHC
- Modulation of the tumor immune microenvironment to promote
anti-tumor activity
- Data supports continued clinical development of ST101 as a
backbone treatment in combination with standard of care and
immune-oncology agents.
The slide presentation described here will be made available on
the Sapience Therapeutics website following the conference.
About ST101
ST101, a first-in-class antagonist
of C/EBPβ, is currently being evaluated in patients with newly
diagnosed and recurrent GBM (ndGBM and rGBM) in the Phase 2 portion
of an ongoing Phase 1-2 clinical study (NCT04478279). In an ongoing
window-of-opportunity sub-study, ST101 is being evaluated as a
monotherapy in rGBM and in combination with radiation and
temozolomide in ndGBM, with patients receiving ST101 before and
after surgical resection. ST101 has been granted Fast Track
designation for rGBM from the U.S. FDA and orphan designations for
glioma from the U.S. FDA and the European Commission.
About Sapience Therapeutics
Sapience Therapeutics, Inc. is a privately held, clinical-stage
biotechnology company focused on discovering and developing peptide
therapeutics to address oncogenic and immune dysregulation that
drive cancer. With in-house discovery capabilities, Sapience
has built a pipeline of therapeutic candidates called
SPEARs™ (Stabilized Peptides Engineered Against
Regulation) that disrupt intracellular protein-protein
interactions, enabling targeting of transcription factors which
have traditionally been considered undruggable, and can direct
cargo to cell surface targets with their new class of molecule
called SPARCs (Stabilized Peptides Against Receptors on Cancer),
enabling delivery of payloads such as α-particles to cancer
cells. Sapience is advancing its lead programs, ST316, a
first-in-class antagonist of β-catenin, and ST101, a first-in-class
antagonist of C/EBPβ, through Phase 1-2 clinical trials.
For more information on Sapience Therapeutics, please
visit www.sapiencetherapeutics.com and engage with us
on LinkedIn.
Cautionary Note on Forward-Looking
Statements
This press release contains forward-looking
statements. Any statements herein other than statements of
historical fact could be deemed to be forward-looking statements.
These forward-looking statements may include, among other things,
statements regarding future events that involve significant risks
and uncertainties (including with respect to Sapience's preclinical
and clinical development programs). These forward-looking
statements are based on management's current expectations, and
actual results and future events may differ materially as a result
of certain factors, including, without limitation, our ability to
obtain additional funds, and meet applicable regulatory standards
and receive required regulatory approvals. Forward-looking
statements speak only as of the date of this press release.
Sapience does not undertake any obligation to update any
forward-looking statements as a result of new information, future
events, changed assumptions or otherwise, except as required by
law.
Media and Investor Contact:
Amy Conrad
Juniper Point
(858) 366-3243
amy@juniper-point.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sapience-therapeutics-to-showcase-clinical-and-biomarker-data-from-st101-phase-2-study-in-gbm-at-asco-2024-302154660.html
SOURCE Sapience Therapeutics, Inc.